CHDArrhythmiasDiabetesLipidologyHeart FailureHypertensionStrokeThrombosis
Log in
Username
Password
Remember me
Bookmark this site|Register Me|Forgotten Password
Welcome to InCirculation.net
InCirculation.net is a professional cardiovascular resource intended for a global audience of specialists, generalists, researchers, and other healthcare professionals
Would you like to know what else InCirculation.net has to offer? Take the tour of InCirculation.net
Click here to register
You can review the latest news articles without logging in, but registration allows you to access all the information and have the choice of receiving an e-mail informing you of the latest updates to the site.

Highlights

  ACC.09 Conference Highlights:
Orlando’s major late-breakers summarised and discussed: JUPITER, ACTIVE-A, ABOARD, PROTECT AF and more


Clinical Trials PowerPoint Slides

Latest Updates

15 June 2009

Editorial: Surgery or PCI for multivessel disease: Doctor’s choice is best
By: Christian Hamm
There is great debate about what treatment is best for multivessel coronary artery disease: PCI or CABG. The SYNTAX trial gave some new insights, but it also confirms what has been reasonable practice already. Christian Hamm reviews the topic.


28 April 2009

Editorial: What is an acute myocardial infarction?
By: Russell V. Luepker
The accurate diagnosis of acute myocardial infarction (AMI) is crucial for therapy, clinical trials and population research. But the diagnosis is in flux as new and more sensitive diagnostic measures become widely available and the presentation of AMI in hospital changes. Russell Luepker discusses these shifts and recent recommendations for the diagnosis of AMI by authoritative bodies.


20 January 2009

Editorial: EUROACTION: Using what we know to improve primary and secondary prevention of coronary heart disease
By: Martin O’Flaherty and Simon Capewell
The delivery of effective evidence-based treatments for primary and secondary prevention is now one of the key strategies in controlling coronary heart disease burden, but there is still no consensus on what is needed and what are the priorities. Martin O’Flaherty and Simon Capewell discuss the results of the EUROACTION trial, which provides insight on what could be achieved by targeting high-risk patients.


All rights reserved. This website is intended for an international audience. Privacy PolicyLegal NoticeTerms and Conditions
Site features